BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liao XY, Liu CY, He JF, Wang LS, Zhang T. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy. Oncol Lett 2019;18:5011-21. [PMID: 31612012 DOI: 10.3892/ol.2019.10893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Pang Q, Wei X, Zhang W, Zhang T, Chen X, Dong J, Wei H, Er P, Zhao J, Han D, Guo Z, Lei T, Du Q, Guan Y, Wang J, Zhao L, Wang J, Yuan Z, Song Y, Liu N, Wang P. Annual report of the esophageal cancer radiation group of the Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital. Ann Transl Med 2020;8:1156. [PMID: 33241005 DOI: 10.21037/atm-20-4064] [Reference Citation Analysis]
2 Dröge LH, Karras PJ, Guhlich M, Schirmer MA, Ghadimi M, Rieken S, Conradi LC, Leu M. Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: Treatment Practice over a 20-Year Period and Implications for the Individual Treatment Modalities. Cancers (Basel) 2021;13:1834. [PMID: 33921384 DOI: 10.3390/cancers13081834] [Reference Citation Analysis]
3 Xu P, Zhang Y, Ge F, Zhang F, He X, Gao X. Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX. Front Oncol 2021;11:637252. [PMID: 34249682 DOI: 10.3389/fonc.2021.637252] [Reference Citation Analysis]
4 Wang X, Zhao Z, Wang P, Geng X, Zhu L, Li M. Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients. Front Oncol 2020;10:997. [PMID: 32656085 DOI: 10.3389/fonc.2020.00997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu L, Wang Y, Li B, Wan G, Liang L, Li T, Lang J, Wang Q. Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT). Front Oncol 2022;12:878851. [DOI: 10.3389/fonc.2022.878851] [Reference Citation Analysis]
6 Sato Y, Motoyama S, Wada Y, Wakita A, Kawakita Y, Nagaki Y, Terata K, Imai K, Anbai A, Hashimoto M, Minamiya Y. Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis. Cancers (Basel) 2021;13:983. [PMID: 33652817 DOI: 10.3390/cancers13050983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang X, Wang P, Zhao Z, Mao Q, Yu J, Li M. A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Ther Adv Med Oncol 2020;12:1758835920926822. [PMID: 32518598 DOI: 10.1177/1758835920926822] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]